TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$100 Million

Revance Therapeutics

Follow-on Offering

Bookrunner, January 2019

Revance Therapeutics
Revance Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of neuromodulators for aesthetic and therapeutic conditions. Revance's lead compound is DaxibotulinumtoxinA for Injection (RT002), which is an injectable neurotoxin that integrates the Company's purified botulinum toxin type A molecule with its proprietary peptide technology. RT002 is being pursued as a treatment for glabellar, forehead and lateral canthal lines (crow's feet) in addition to multiple therapeutic conditions including cervical dystonia, plantar fasciitis, upper limb spasticity and chronic migraines